Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction
<p dir="ltr">Although previous cost‐effectiveness evaluations of sacubitril/valsartan have demonstrated cardiovascular and economic benefits in heart failure patients with reduced ejection fraction (HFrEF), whether sacubitril/valsartan is cost-effective for reducing the need for impl...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513538542796800 |
|---|---|
| author | Rasha Kaddoura (12506936) |
| author2 | Dina Abushanab (10696501) Abdul Rahman Arabi (12506942) Sumaya Alsaadi Alyafei (17380426) Daoud Al-Badriyeh (832403) |
| author2_role | author author author author |
| author_facet | Rasha Kaddoura (12506936) Dina Abushanab (10696501) Abdul Rahman Arabi (12506942) Sumaya Alsaadi Alyafei (17380426) Daoud Al-Badriyeh (832403) |
| author_role | author |
| dc.creator.none.fl_str_mv | Rasha Kaddoura (12506936) Dina Abushanab (10696501) Abdul Rahman Arabi (12506942) Sumaya Alsaadi Alyafei (17380426) Daoud Al-Badriyeh (832403) |
| dc.date.none.fl_str_mv | 2022-12-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.cpcardiol.2022.101385 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Cost-Effectiveness_Analysis_of_Sacubitril_Valsartan_for_Reducing_the_Use_of_Implantable_Cardioverter-Defibrillator_ICD_and_the_Risk_of_Death_in_ICD-Eligible_Heart_Failure_Patients_with_Reduced_Ejection_Fraction/24551437 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Health sciences Health services and systems Cost-Effectiveness Analysis Sacubitril/Valsartan Implantable Cardioverter-Defibrillator (ICD) |
| dc.title.none.fl_str_mv | Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Although previous cost‐effectiveness evaluations of sacubitril/valsartan have demonstrated cardiovascular and economic benefits in heart failure patients with reduced ejection fraction (HFrEF), whether sacubitril/valsartan is cost-effective for reducing the need for implantable cardioverter-defibrillator (ICD) implantation and the risk of death in ICD‐eligible patients has not been investigated in patients with HFrEF. Herein, we evaluated the cost-effectiveness of sacubitril/valsartan versus standard of care in reducing the need for ICD implantation and the death rate in HFrEF. A Markov model was developed from the Qatari hospital perspective, comprised of ‘survival’ and ‘death’ health states, and was based on 1-monthly Markovian cycles, a 20-years follow-up horizon, and a 3% discount rate. The model inputs were obtained from the literature and local sources. Sacubitril/valsartan resulted in a relative increase of 0.04 quality-adjusted life year (QALY) and 0.67 years of life lived (YLL)/person, with an incremental cost increase of QAR13,952 (USD3,832). Sacubitril/valsartan was associated with incremental cost effectiveness ratio of QAR341,113 (USD93,687)/QALYs gained and QAR24,431 (USD6,710)/YLL. Sensitivity analyses confirmed robustness, with the cost-effectiveness maintained in ≥96.5% of simulated cases. To conclude, sacubitril/valsartan is a cost-effective alternative to standard care against QALY gained and YLL in reducing the need for an ICD therapy and the rate of death among ICD-eligible HFrEF patients.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2022.101385" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2022.101385</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_e3dab932e059eb2f0182e7b8751aeb68 |
| identifier_str_mv | 10.1016/j.cpcardiol.2022.101385 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/24551437 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection FractionRasha Kaddoura (12506936)Dina Abushanab (10696501)Abdul Rahman Arabi (12506942)Sumaya Alsaadi Alyafei (17380426)Daoud Al-Badriyeh (832403)Biomedical and clinical sciencesCardiovascular medicine and haematologyPharmacology and pharmaceutical sciencesHealth sciencesHealth services and systemsCost-EffectivenessAnalysisSacubitril/ValsartanImplantable Cardioverter-Defibrillator (ICD)<p dir="ltr">Although previous cost‐effectiveness evaluations of sacubitril/valsartan have demonstrated cardiovascular and economic benefits in heart failure patients with reduced ejection fraction (HFrEF), whether sacubitril/valsartan is cost-effective for reducing the need for implantable cardioverter-defibrillator (ICD) implantation and the risk of death in ICD‐eligible patients has not been investigated in patients with HFrEF. Herein, we evaluated the cost-effectiveness of sacubitril/valsartan versus standard of care in reducing the need for ICD implantation and the death rate in HFrEF. A Markov model was developed from the Qatari hospital perspective, comprised of ‘survival’ and ‘death’ health states, and was based on 1-monthly Markovian cycles, a 20-years follow-up horizon, and a 3% discount rate. The model inputs were obtained from the literature and local sources. Sacubitril/valsartan resulted in a relative increase of 0.04 quality-adjusted life year (QALY) and 0.67 years of life lived (YLL)/person, with an incremental cost increase of QAR13,952 (USD3,832). Sacubitril/valsartan was associated with incremental cost effectiveness ratio of QAR341,113 (USD93,687)/QALYs gained and QAR24,431 (USD6,710)/YLL. Sensitivity analyses confirmed robustness, with the cost-effectiveness maintained in ≥96.5% of simulated cases. To conclude, sacubitril/valsartan is a cost-effective alternative to standard care against QALY gained and YLL in reducing the need for an ICD therapy and the rate of death among ICD-eligible HFrEF patients.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2022.101385" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2022.101385</a></p>2022-12-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.cpcardiol.2022.101385https://figshare.com/articles/journal_contribution/Cost-Effectiveness_Analysis_of_Sacubitril_Valsartan_for_Reducing_the_Use_of_Implantable_Cardioverter-Defibrillator_ICD_and_the_Risk_of_Death_in_ICD-Eligible_Heart_Failure_Patients_with_Reduced_Ejection_Fraction/24551437CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/245514372022-12-01T00:00:00Z |
| spellingShingle | Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction Rasha Kaddoura (12506936) Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Health sciences Health services and systems Cost-Effectiveness Analysis Sacubitril/Valsartan Implantable Cardioverter-Defibrillator (ICD) |
| status_str | publishedVersion |
| title | Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction |
| title_full | Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction |
| title_fullStr | Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction |
| title_full_unstemmed | Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction |
| title_short | Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction |
| title_sort | Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Health sciences Health services and systems Cost-Effectiveness Analysis Sacubitril/Valsartan Implantable Cardioverter-Defibrillator (ICD) |